CLAIM #56607 · Thermo Fisher Scientific Inc (TMO) · 2025Q4 earnings call · Jan 29, 2026 · due Dec 31, 2026
“After factoring in the financing costs, they represented 7¢ of adjusted EPS dilution for 2026.”
Stephen Williamson · CFO
How to check this claim
Look at: Dilution to adjusted EPS from 2025 acquisitions (financing costs included), fiscal year 2026
It came true if: Reported acquisition-related adjusted EPS dilution for FY2026 = $0.07 (within $0.01)
Where: Company adjusted EPS reconciliation / management commentary on Q4 2026 earnings call or FY2026 10-K
In context
“uld represent roughly one additional point of adjusted EPS growth for 2026, taking the total company growth into the range of 7% to 9%. In terms of the macro environment, our guidance is based on the tariffs that are in place as of today. It doesn't contemplate any future changes in tariffs nor their potential impact on FX rates. Should additional tariffs be levied, as we did last year, we will act with speed and scale to minimize them and provide our usual level of transparency as to their impact. The guidance includes $600 million of inorganic revenue from the acquisitions closed in 2025. In that inorganic period, these acquisitions are expected to contribute $60 million of adjusted operating income. The math of which adds a 20 basis point headwind to adjusted operating margins in 2026. After factoring in the financing costs, they represented 7¢ of adjusted EPS dilution for 2026. These acquisitions are progressing well versus our deal model expectations. We're in the integration and investment phase in 2026, which is setting us up to deliver strong accretion and very attractive returns going forward. To help you with your modeling, here are a few additional assumptions behind the guide. We expect approximately $500 million of net interest expense in 2026. We assume that the adjusted income tax rate will be 11.5% in 2026, largely driven by the increased earnings. We're expecting between 1.8% and $2 billion of net capital expenditures in 2026. The increase over '25 is driven by our investments in US manufacturing. In terms of free cash flow, we're expecting that to be in the range of $6.8 billion to $7.3 billion for the year. In terms of capital deployment, we're as”
Verify independently
SEC filings for TMO ↗ · Claim quote is verbatim from the 2025Q4 earnings call.